Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
نویسندگان
چکیده
منابع مشابه
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.
PHARMACOLOGY Research into the role of gut hormones in the regulation of pancreatic beta-cell function has led to new targets in the management of type-2 diabetes. It is known that eating food leads to the release of multiple hormones that regulate gut motility, the secretion of gastric and pancreatic enzymes, the contraction of the gallbladder, and the absorption of various nutrients.3 Several...
متن کاملDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
BACKGROUND In type 2 diabetes mellitus there is a progressive loss of beta-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. OBJECTIVES To assess the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. SEARCH STRATEGY Studies were obtained from...
متن کاملDiabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?
Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some hav...
متن کاملCardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase...
متن کاملDipeptidyl Peptidase-4 Inhibitors and Bone Fractures
OBJECTIVE Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far. RESEARCH DESIGN AND METHODS A meta-analysis was performed including all randomized clinical trials with a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Diabetology
سال: 2016
ISSN: 2450-8187,2450-7458
DOI: 10.5603/dk.2015.0027